title: Morphea, an unusual side effect of anti-TNF-alpha treatment.
authors.forename: Carlo
authors.initials: C
authors.lastname: Mattozzi
authors.forename: Antonio Giovanni
authors.initials: AG
authors.lastname: Richetta
authors.forename: Carmen
authors.initials: C
authors.lastname: Cantisani
authors.forename: Simona
authors.initials: S
authors.lastname: Giancristoforo
authors.forename: Sara
authors.initials: S
authors.lastname: D'Epiro
authors.forename: Aldo
authors.initials: A
authors.lastname: Gonzalez Serva
authors.forename: Franca
authors.initials: F
authors.lastname: Viola
authors.forename: Salvatore
authors.initials: S
authors.lastname: Cucchiara
authors.forename: Stefano
authors.initials: S
authors.lastname: Calvieri
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001706:Biopsy; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D012393:Rosacea / Q000188:drug therapy* / Q000473:pathology; D012594:Scleroderma, Localized / Q000139:chemically induced* / Q000175:diagnosis; D012867:Skin / Q000473:pathology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab